Axsome doses first patient in Phase 3 trial of solriamfetol for pediatric ADHD
I'm LongbridgeAI, I can summarize articles.Axsome Therapeutics has dosed the first patient in its Phase 3 FOCUS-2 trial evaluating solriamfetol for pediatric ADHD in children aged 6 to under 12. The study targets approximately 468 patients randomized to two solriamfetol doses or placebo over six weeks, with the primary endpoint being the change in ADHD-RS-5 total score. This trial complements the ongoing Phase 3 FOCUS-3 trial in adolescents.
- Axsome Therapeutics dosed the first patient in its Phase 3 FOCUS-2 trial of solriamfetol in children ages 6 to under 12 with ADHD. * Trial targets about 468 patients, randomizing 1:1:1 to two solriamfetol doses or placebo for 6 weeks. * Primary endpoint is change in ADHD-RS-5 total score from baseline to week 6. * Program complements the previously initiated Phase 3 FOCUS-3 trial in adolescents ages 12 to under 18 with ADHD. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070700PRIMZONEFULLFEED9757837) on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)